Propel(x) is a Franklin Templeton Evo Nexus Incubator Portfolio Company
Vaccine development in general on average takes 8-15 years. So even the talk about having a vaccine in the next 12-18 months since the pandemic started is breathtakingly optimistic.
Considering the challenges and complications around developing a coronavirus vaccine, when COVID-19 vaccine is finally ready, will the world be? How safe and efficient will this vaccine be?
This meeting is for informational purposes only. It is not a solicitation or offer to purchase or sell any security, nor should this information be construed as advice for investment decisions.
Private Placements are a high-risk investment. An investment in this offering is speculative and an investor could experience an entire loss of principal. Private investments are highly illiquid and risky and are not suitable for all investors. There is no guarantee that an investment will be profitable or that there will ever be an exit strategy or an opportunity to liquidate the investment. Investments in early-stage private companies should only be part of your overall investment portfolio.